Interleukin-6 downregulation with mesenchymal stem cell differentiation results in loss of immunoprivilege

Journal of Cellular and Molecular Medicine

Volumn 17, Issue 9, 2013, Pages 1136-1145

  Li, Peng ^a,b   Li, Shu Hong ^b   Wu, Jun ^b   Zang, Wang Fu ^a   Dhingra, Sanjiv ^b   Sun, Lu ^b   Weisel, Richard D ^b   Li, Ren Ke ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cell differentiation; Immune rejection; Immunoprivilege; Interleukin 6; Mesenchymal stem cell

Indexed keywords

HYDROGEN PEROXIDE; INTERLEUKIN 6;

ANIMAL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CYTOLOGY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; IMMUNE REJECTION; IMMUNOLOGY; IMMUNOPRIVILEGE; LEUKOCYTE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; METABOLISM; MUSCLE DEVELOPMENT; PHENOTYPE; RAT; WISTAR RAT;

CELL DIFFERENTIATION; IMMUNE REJECTION; IMMUNOPRIVILEGE; INTERLEUKIN-6; MESENCHYMAL STEM CELL;

ANIMALS; CELL DEATH; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; HYDROGEN PEROXIDE; INTERLEUKIN-6; LEUKOCYTES; MESENCHYMAL STROMAL CELLS; MUSCLE DEVELOPMENT; PHENOTYPE; RATS; RATS, WISTAR;

EID: 84884818950     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12092     Document Type: Article

References (23)

1. Fedak PW, Verma S, Weisel RD, et al. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol. 2005; 14: 1-11.
2. Huang XP, Sun Z, Miyagi Y, et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation. 2010; 122: 2419-29.
3. Lau P, Amadou C, Brun H, et al. Characterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites. BMC Immunol. 2003; 4: 7.
4. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31: 890-6.
5. Davani S, Marandin A, Mersin N, et al. Mesenchymal progenitor cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a rat cellular cardiomyoplasty model. Circulation. 2003; 108: II253-8.
6. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005; 112: 1128-35.
7. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002; 105: 93-8.
8. Brunt KR, Zhang Y, Mihic A, et al. Role of WNT/beta-catenin signaling in rejuvenating myogenic differentiation of aged mesenchymal stem cells from cardiac patients. Am J Pathol. 2012; 181: 2067-78.
9. Fan M, Chen W, Liu W, et al. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. 2010; 13: 429-38.
10. Imanishi Y, Saito A, Komoda H, et al. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol. 2008; 44: 662-71.
11. Amado LC, Saliaris AP, Schuleri KH, et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005; 102: 11474-9.
12. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009; 54: 2277-86.
13. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105: 1815-22.
14. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009; 15: 42-9.
15. Park CW, Kim K-S, Bae S, et al. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J Stem Cells. 2009; 2: 59-68.
16. Spaggiari GM, Capobianco A, Abdelrazik H, et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2. Blood. 2008; 111: 1327-33.
17. Bouffi C, Bony C, Courties G, et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE. 2010; 5: e14247.
18. Djouad F, Charbonnier LM, Bouffi C, et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells. 2007; 25: 2025-32.
19. Chan CK, Wu KH, Lee YS, et al. The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSCs, and adult-type MSCs. Transplantation. 2012; 94: 132-8.
20. Najar M, Rouas R, Raicevic G, et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy. 2009; 11: 570-83.
21. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res. 2004; 95: 9-20.
22. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109: 923-40.
23. Shabbir A, Zisa D, Lin H, et al. Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol. 2010; 299: H1428-38.